



ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

CLINICAL TRIAL UPDATE

EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to provide an update on the progress of its clinical trial and its access to resources during the ongoing COVID-19 pandemic. At present, the Company is progressing the trial in line with its original six month timeline. To date, the COVID-19 pandemic, whilst affecting health care infrastructure and the wider community, has not impacted the enrolment rate of patients or the generation and processing of data necessary for the clinical trial. Nevertheless, the Company’s ability to continue to progress the trial in accordance with its proposed timeframe will depend on its ability to continue to access resources, such as suitably qualified personnel, over the coming months.

During the trial, the Company’s primary objective is to collect imaging data from stroke patients that allows refinement and selection of the optimal imaging algorithms as well as early data on correlation of images generated by the Company’s technology with CT and/or MRI imaging. The primary endpoint of EMVision’s pilot clinical trial is to generate a dataset of stroke patient scans which improves the understanding of stroke on electromagnetic scattering effects in the brain. The single centre study will enrol 30 diagnosed stroke patients with confirmatory CT and/or MRI. No intervention or modification to the usual hospital-based treatment of stroke is proposed as part of this trial.

To date, a significant number of the target 30 patients with different stroke subtypes have been enrolled and scanned in the study. Each patient has received multiple scans. Patients continue to be enrolled in the study. The datasets that have already been acquired provide the imaging algorithm and product development team with valuable learnings to continue the product development process. This includes the fine tuning of our imaging algorithms and selection of the optimal “fusion” of advanced algorithms for our planned commercial product. The Company intends to update the market with preliminary observations, images and results as soon as they are available.

To manage the evolving COVID-19 situation, the Company has a number of risk mitigation processes in place. The trial team that is responsible for enrolling patients has multiple personnel redundancies built in. Within the team are several clinicians who have been trained in the operation of the EMVision brain scanner which allows for progress in the absence of some staff. The algorithm team are processing datasets remotely and continue to do so. The COVID-19 situation is dynamic and the Company will provide updates if there are any material changes to the progress of the trial.

The Company had \$6.87 million cash as at 31 December 2019 and remains well funded to complete the clinical trial.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.5 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.